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Abstract Prostate cancer is the most frequently diag-
nosed malignant neoplasm in men in the developed
countries. Although the progression of prostate cancer
and the processes of invasion and metastasis by tumor
cells are comparatively well understood, the genes in-
volved in these processes are not fully determined.
Therefore, a common area of research interest is the
identification of novel molecules that are involved in
these processes. In the present study, we have used in
silico and experimental approaches to compare the ex-
pression of embryonal Fyn-associated substrate (EFS)
between normal prostate and prostate cancer. We
showed that EFS expression is remarkably downregulat-
ed in prostate cancer cells, compared to normal prostate
cells. We also found that decreased expression of EFS in
prostate cancer cells is due to DNA methylation. In addition,
we showed that high EFS expression is important to suppress
a malignant behavior of prostate cancer cells. Therefore, we
suggest that EFS should be considered as a novel tumor
suppressor gene in prostate cancer.
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Abbreviations
PCa Prostate cancer
EFS Embryonal Fyn-associated substrate
CAS Crk-associated substrate
BCAR1 Breast cancer resistance 1
NEDD9 Neural precursor cell expressed, developmentally
downregulated 9
HEPL HEF1-EFS-P130 Cas-like
FBS Fetal bovine serum
5-Aza 5′-Aza-2′-deoxycytidine
TSA Trichostatin A
TBS-T Tris-buffered saline containing 0.1 % Tween 20
PVDF Polyvinyledine fluoride
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
Introduction
Prostate cancer (PCa) is the most common form of cancer,
excluding skin cancer, in men in the developed countries with
increasing rates in the developing world [1]. Although the
progression of PCa and the processes of invasion and metas-
tasis by tumor cells are comparatively well understood, the
genes involved in these processes are not fully determined.
Therefore, various approaches have been used to fully under-
stand the molecular basis of these processes. Differential
expression of some genes is accepted as a marker in both
development and progression of cancer. Therefore, the gene
expression profiling has been extensively used to identify
novel diagnostic and prognostic biomarkers [2, 3]. In several
studies, correlations between tumor expression alterations and
clinical outcome have been identified in PCa [4, 5]. Consis-
tently, some genes reported as differentially expressed in PCa
may reflect the differences between metastatic and organ-
confined tumors [6, 7]. Recently, using database-based
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transcriptomics approaches, we reported that several genes are
downregulated and may be involved in progression and me-
tastasis of the disease in PCa [8]. In the present study, we have
used the same approach as a starting point to show embryonal
Fyn-associated substrate (EFS) as a differentially expressed
gene in PCa.
Crk-associated substrate (CAS) family is composed of
breast cancer resistance 1 (BCAR1) [9]; neural precur-
sor cell expressed, developmentally downregulated 9
(NEDD9) [10]; HEF1-EFS-P130 Cas-like (HEPL) [11];
and EFS [12] which have important roles in both nor-
mal cellular physiology and malignant transformation
[13]. Although EFS (UniProt number=043281) was
identified as a CAS family member, there is no any
study on the function of EFS, up to date. However, it
was shown that EFS interacts with Src, Fyn, and Yes
which are Src family kinases, via an SH3 domain, like
other CAS family members [12, 14]. Therefore, it was sup-
posed that EFS may be an adapter molecule, like other CAS
family proteins that are regulated by phosphorylation-
dependent mechanisms [15]. Although there are several re-
ports on the relationship between other CAS family members
and cancer, there is only one report on the EFS expression in
carcinogenesis. In that report, Neumann et al. have shown that
bi-allelic methylation of EFS promoter is a common event in
melanoma and which has been associated with poor prognosis
[16].
In the present study, we have used in silico and experimen-
tal approaches to investigate EFS expression in prostate cells.
We demonstrate that EFS expression is downregulated in PCa
cells compared to normal prostate. Our results also reveal that
the ectopic EFS expression decreases cell proliferation, cell
migration, and colony formation abilities of PCa cells. In
summary, our findings provide further insight for the anti-
oncogenic role of EFS in mediating PCa tumorigenesis.
Material and methods
In silico analysis
We used Oncomine Cancer Microarray database (http://www.
oncomine.org/) [17] in order to compare the gene expression
of EFS in a tumor sample to its normal counterpart, and gene
expression data from the same study, performed with the same
methodology, were used as described previously [18, 19]. The
gene expression data were log transformed and median
centered per array, and the standard deviation was
normalized to one per array [17]. A gene was considered as
underexpressed when its mean value in tumor samples was
significantly lower to its mean value in the normal tissue
counterpart using a t test (≤0.001), and the fold of induction
was ≤−2.
Cell lines and culture conditions
PC-3, DU145, and LNCaP PCa cells were kindly provided by
Dr. Kemal S. Korkmaz from Ege University, Turkey. PNT1a
cells were kindly provided by Dr. Ö. Faruk Bayraktar from
Yeditepe University, Turkey. The cells were propagated in
RPMI 1640 or DMEM/F12 (Gibco, USA) supplemented with
5–10 % fetal bovine serum (FBS), L-glutamine (2 mM), pen-
icillin (100 U/ml), and streptomycin (100 μg/ml) and were
cultured in 5 % CO2 environment in a humidified incubator at
37 °C.
Primer design, plasmid construct, and transfections
The full-length open reading frame of EFS was amplified
using a forward primer (GAAGGAGATACCACCATGGCC
ATTGCCACGTCGAC) and a reverse primer (GGGCACGT
CATACGGTGGAGCCAGGCTAGTGAG), which were de-
signed using Primer 3 software. The PCR product was cloned
into a linearized pME-HA (Lucigen, USA) vector according
to the manufacturer’s recommendations. The inserts were
verified by PCR amplification. All transfections were per-
formed using FuGENE HD (Promega, USA) transfection
reagent according to the manufacturer’s recommendations.
Briefly, cells were seeded in 60-mm plates at 60% confluency
1 day prior to transfection. In the following day, the transfec-
tion solution was prepared in a 1.5-ml microcentrifuge tube by
adding 3 μl of FuGENE HD transfection reagent into 100 μl
of pre-warmed DMEM/F12 or RPMI 1640 and was incubated
for 5 min, and 1 μg of pME-HA-EFS plasmid DNA was
added. The mixture was added to the cells drop-wise after
incubating for 15 min at room temperature.
Antibodies and immunoblotting
Cells were lysed with ice-cold RIPA buffer (1 % Nonidet
P-40, 50 mM Tris–Cl, pH 7.4, 0.25 % Na deoxycholate,
150 mM NaCl), including 1 mM NaF, 1 mM EDTA, and
1 mM Na3VO4, complete protease and phosphatase inhibitor
cocktails (BioVision, USA), unless otherwise indicated. Ten
percent of SDS–polyacrylamide gels were used for separation,
and the proteins were immobilized onto polyvinylidene fluo-
ride (PVDF) membranes (Bio-Rad, USA) using a wet transfer
blotter. Briefly, membranes were blocked using Tris-buffered
saline containing 0.1 % Tween 20 (TBS-T) containing 5 %
skim milk (w/v). Antibody incubations were performed using
TBS-T containing 0.5 % skim milk at room temperature (RT)
for 1 h or at 4 °C overnight. Membranes were developed using
Clarity Western ECL Substrate (Bio-Rad, USA) for 5 min and
were photographed using Kodak X-ray films in a dark room.
EFS and β-actin antibodies were purchased from Bios
(Gräfelfing, Germany) and Santa Cruz Biotechnology, Inc.
(Bergheimer, Germany), respectively.
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Total RNA isolation and RT-PCR
Total RNA was isolated from cultured PC-3, DU145, and
LNCaP cells using the RNeasy kit (Qiagen, CA), and yields
were calculated by absorbance readings at 260 nm. Using
anchored oligo-dT primers, 2 μg of total RNAwas reversely
transcribed to make complementary DNA (cDNA) using the
Omniscript kit (Qiagen, CA). The resultant cDNA was then
used in PCR reactions and analyzed by agarose gel electro-
phoresis. The following primers were used: EFS forward:
TGGCCGAGGAGTATGAC, EFS reverse: TCTCCGGTGG
ACACAAC; glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) forward: CATTGCCCTCAACGACCACTTT,
and GAPDH reverse: GGTGGTCCAGGGGTCTTACTCC.
PCR conditions were as follows: 94 °C for 2 min, followed
by 35 cycles of 94 °C for 30 s, 56 °C for 30 s, and 72 °C for
2 min. The final extension was at 72 °C for 2 min.
Proliferation, migration, and colony formation assays
PC-3, DU145, and LNCaP cells were plated in 60-mm plates.
Twenty-four hours after plating, cells were transfected with an
empty vector or a full-length EFS using FuGENE HD as
suggested by the manufacturer. On the next day (day 1), cells
were trypsinized and plated in triplicates in 96-well dishes at a
concentration of 4×103 cells/well. Cell proliferation was mea-
sured using WST-1 assay kit (BioVision, USA) at designated
time points, and relative proliferation was calculated by nor-
malizing to day 1 values. Colony formation assays were
performed as described previously [20]. Briefly, PC-3,
DU145, and LNCaP cells were transfected with an empty
vector or an EFS. After 24 h of transfection, cells were
trypsinized and seeded on new six-well plates (5×103 cells
for PC-3 and DU145 and 1×104 cells for LNCaP) and cul-
tured for 2 weeks in DMEM/F12 or RPMI 1640, supplement-
ed with 5–10 % FBS. Cells were then fixed with −20 °C cold
methanol for 30 min. Colonies were stained with crystal violet
(0.2 %), and the area covered on each plate by the colonies
was measured using a colony counter software program [21].
An in vitro wound-healing model (streak assay) was used to
detect migration differences between vector and EFS-
transfected PC-3 cells, as described previously [20]. In this
assay, sub-confluent PC-3 cells were transfected with vector
or EFS, and 24 h later, confluent cells were scarped with a blue
pipette tip and rinsed with PBS to remove any floating cells.
Then, fresh medium was added and images of multiple re-
gions were taken 0 and 24 h after scarping.
5′-Aza-2′-deoxycytidine and trichostatin A treatment
Treatments were performed as described previously [22].
Briefly, PC-3 cells were seeded at a density of 1×106 cells/
60-mm dish and allowed to attach for 24 h. In the following
day, 10 μM 5-aza (Sigma, St. Louis, MO) was added to the
medium for 72 h. At every 24-h interval, fresh medium
containing the drug was added. For the synergistic study, cells
were first incubated with 10 μM 5'-aza-2'- deoxycytidine (5-
aza) for 56 h at 37 °C and then 50 nM trichostatin A (TSA)
(Sigma, St. Louis, MO) was added for an additional 16 h (total
72 h).
Results
Loss of EFS expression is associated with advanced PCa
To investigate how EFS expression is altered in PCa, we used
Oncomine to analyze published microarray data, as described
previously [8, 18, 19]. The results showed that the levels of
EFS messenger RNAs (mRNAs) are lower in PCa tissues
when compared with normal tissues, in six independent stud-
ies [4, 23–27] (Table 1). Furthermore, EFS mRNA levels
decrease in the higher Gleason score samples compared to
lower score samples [28] (Fig. 1a). Oncomine data also re-
vealed a decrease in EFS mRNAs in metastatic tumors when
compared with the primary tumors [29] (Fig. 1b).
EFS expression in prostate cells
Since in silico results revealed that EFS expression is down-
regulated in PCa, we examined the expression of the EFS by
Western blotting using three cancer cell lines and one normal
prostate cell line. We found that EFS expression is remarkably
high in normal prostate at both mRNA (Fig. 2a) and protein
levels (Fig. 2b). However, the EFS level is very low in PC-3
and LNCaP PCa cells (Fig. 2a, b). Although EFS protein
levels were readily detectable in DU145 cells compared to
PC-3 and LNCaP cells, it was remarkably lower than normal
prostate cell line PNT1a (Fig. 2a, b). Because both DNA
Table 1 EFS is downregulated in prostate cancer. Analysis of the PCa
datasets deposited in Oncomine database showed decreased expression of
EFS in PCa compared to normal prostate. Underexpression of EFS was
considered when its mean expression value in the tumor samples was
significantly lower than that of the normal tissue counterpart using a t test
(P<0.001), and the fold of induction was ≤−2
Dataset Fold change
(cancer/normal)
P value References
LaTulippe Prostate −4.645 8.74E−11 [23]
Tomlins Prostate −3.499 2.59E−08 [24]
Arredouani Prostate −3.044 1.20E−05 [25]
Luo Prostate 2 −2.747 4.78E−04 [26]
Singh Prostate −2.337 2.56E−04 [4]
Grasso Prostate −2.109 9.14E−15 [27]
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methylation and histone deacetylation are common epigenetic
events in cancers that regulate gene expression at the promoter
level, we checked whether inhibition of the activities of DNA
methyltransferases, using 5-aza, and/or histone deacetylases,
using TSA, could restore the expression of EFS in PCa cell
line PC-3 which has a very low EFS level. The results showed
that the treatment of the cells with the deacetylase inhibitor
TSA had little effect; however, when 5-aza was used alone or
in combination with TSA, there was a dramatic increase in
EFS mRNA (Fig. 2c) and protein (Fig. 2d) levels.
Increased expression of EFS repressed malignant behavior
of PCa cells
Our in silico results showed that decreased expression of EFS
is associated with aggressive PCa. Therefore, we assumed that
increased expression of EFS in the PCa cells may suppress the
malignant phenotype. Firstly, we cloned full-length human
EFS to a mammalian expression vector and then transiently
transfected PC-3, DU145, and LNCaP PCa cells with full-
length EFS or empty vector to evaluate the potential role of
EFS as a tumor suppressor in these cells. We first noticed a
change in the growth rates between EFS and vector-
transfected cells. EFS overexpression caused a decrease in
cell proliferation in all of the cancer cells which were used
in this study (Fig. 3b). On the other hand, it is known that for a
cancer cell to metastasize, the cells must migrate from the
primary tumor and enter the circulation system [30]. There-
fore, we investigated the effect of EFS overexpression on cell
migration by wound-healing assay. The assay was performed
within 24 h to minimize secondary effects of cell proliferation.
The results showed a dramatic decrease in cell migration when
EFS was overexpressed, compared to the vector-transfected
cells, in concordance with in silico results. Furthermore, the
frequency of the colony formation in the cells that were
transfected with full-length EFS was significantly lower than
that of the cells with an empty vector, in agreement with the
above results.
Fig. 1 EFS expression is further decreased in advanced PCa. a The level
of EFS is lower in Gleason score 9 compared to Gleason score 6. b EFS
mRNA expression is lower in metastatic PCa compared to primary tumor.
Oncomine was used for the analysis of expression data. Student’s t test
was used for differential expression analysis, and P values are shown on
the figures. Y axis of the graphs represents log2 median-centered ratios,
dots are maximum and minimum values, boxes are 75th and 25th per-
centiles, and whiskers are the 90th and 10th percentiles. Sample sizes are
shown in parentheses on the figures
Fig. 2 EFS expression in prostate cells. a The EFS mRNA and b EFS
protein levels are downregulated in PC-3, DU145, and LNCaP PCa cells
as compared to PNT1, a normal prostate cell line. Since different cells
were used in A and B experiments which have different expression levels
of GAPDH and β-actin, total mRNA and protein were also used as
loading control, respectively. 5-Aza and TSA treatment restored EFS
mRNA (c) and protein (d) levels in PC-3 PCa cells. GAPDH was used
as loading control for RT-PCR and β-actin for Western blotting. The
expression of EFS mRNA (a and c) and EFS protein (b and d) were
analyzed by RT-PCR and Western blotting, respectively
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Discussion
In the present study, we have provided the first evidence that
decreased expression of EFS is associated with the develop-
ment and progression of PCa. The analysis of public data
deposited in Oncomine cancer transcriptomics database re-
vealed that EFS expression is significantly downregulated in
PCa, compared to normal prostate tissues. In concordance, we
have seen that EFS is downregulated in PCa cell lines at both
mRNA and protein levels, compared with normal prostate
epithelial cells. Since Neumann et al. showed that the promot-
er of EFS is methylated in melanoma cells and this event is
associated with poor prognosis, we investigated putative pro-
moter methylation of EFS in PC-3 PCa cells using DNA
methyltransferase and histone deacetylase inhibitors. Indeed,
we have seen that inhibition of DNA methyl transferases and
histone deacetylases resulted to increased expression of EFS
at both mRNA and protein levels. Therefore, we suggest that
promoter methylation may cause downregulation of EFS ex-
pression in the PCa cells.
The analysis of Oncomine also revealed that decreased
expression of EFS is associated with advanced and aggressive
PCa. To asses this idea, we have cloned EFS to a mammalian
expression vector and transiently transfected PCa cell lines to
investigate whether high EFS level will change a malignant
behavior of PCa cells. Indeed, we have seen that high EFS
level repressed cell proliferation, migration, and colony for-
mation abilities of all the investigated PCa cells.
Donlin et al. reported that EFS is an important regulator in
T lymphocyte development and that EFS deficiency leads to
Fig. 3 Overexpression of EFS repressesmalignant behavior of PCa cells.
a Transfection of EFS construct lead to increased EFS protein in PC-3,
DU145, and LNCaP cells. b The effect of EFS overexpression on
proliferation of PCa cells. The cell growth of vector or EFS-transfected
PC-3, DU145, and LNCaP cells was examined by WST-1 assay over
3 days. The results represent the mean±SD of three independent exper-
iments. P<0.05 as determined by Student’s t test. c Effect of EFS
overexpression on wound healing in PC-3 prostate cancer cells. Sub-
confluent PC-3 cells were transfected with vector or EFS, and 24 h later,
confluent cells were scarped with a blue pipette tip. The wounded area
was imaged at 0 time and 24 h after injury. d, e The effect of EFS
overexpression on colony formation abilities of PCa cells. Vector or
EFS-transfected PC-3, DU145, and LNCaP cells were incubated in a
six-well plate and cultured for 2 weeks and then photographed after
staining by crystal violet. The results represent the mean±SD of three
independent experiments (*P<0.05)
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aberrant T cell activation and, consequently, inflammation
[31, 32]. It is known that the inflammation contributes to
cancer development and progression [33]. Therefore, EFS
deficiency-dependent malignant behavior changes may be
linked to inflammation-related processes. In addition, it was
shown that BCAR1 and NEDD9which are the other members
of CAS family regulate membrane localization of E-cadherin
and its interaction with catenin molecules [34]. Therefore,
another possible mechanism to explain the role of EFS may
be via the regulation of E-cadherin/β-catenin signalling. Al-
though these hypotheses may open new doors to better under-
stand the relationship between inflammation and/or E-
cadherin/β-catenin and cancer, it needs further investigation.
In summary, we have successfully combined the in silico
analysis and experimental approaches to find a new gene
involved in the development and progression of PCa. We also
provide ample evidence that EFS should be categorized as a
tumor suppressive in PCa. We also suggest that restoration of
EFS expression may be a potential therapeutic strategy for the
treatment of prostate cancer. Molecular mechanism by which
EFS exerts its tumor-suppressive role needs to be further
investigated.
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